Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 7/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330829 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4898660 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL851964 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM4ETDP1ERN1 | |
| SCHEMBL29953692 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM4ETDP1ERN1 | |
| SCHEMBL29628664 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4011543 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10658941 | 0.79 | ERN1 (0.58) | ALDH1A1ERN1TLR2TLR1TLR6 | |
| SCHEMBL17858436 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10541475 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP1A2TSHRKDM4ETDP1 | |
| SCHEMBL29818683 | 0.78 | ALDH1A1 (0.48) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020114477-A1 | COMPOUND ACTING AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海济煜医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-1370213-A4 | ASYMMETRIC BENZALDEHYDE ALDITOL DERIVATIVES, METHODS OF MAKING THEREOF, AND COMPOSITIONS AND ARTICLES CONTAINING SAME | MILLIKEN & CO (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1370213-A2 | ASYMMETRIC BENZALDEHYDE ALDITOL DERIVATIVES, METHODS OF MAKING THEREOF, AND COMPOSITIONS AND ARTICLES CONTAINING SAME | Milliken & Company (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6548581-B2 | Radiation transparent polyolefin | MILLIKEN & COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030013786-A1 | Novel asymmetric halogen-alkyl alditol derivatives as nucleators and clarifiers for polyolefins, and polyolefin plastic compositions containing same | MILLIKEN & COMPANY | 2003-01-16 | — | — | US | disclosed |
| WO-2002076385-A2 | ASYMMETRIC BENZALDEHYDE ALDITOL DERIVATIVES, METHODS OF MAKING THEREOF, AND COMPOSITIONS AND ARTICLES CONTAINING SAME | MILLIKEN & COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ALDH1A1 3347/4885HPGD 2073/4885CYP1A2 1721/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ALDH1A1 3347/4885HPGD 2073/4885CYP1A2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.